Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $97.50 short put and a strike $92.50 long put offers a potential 15.74% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $97.50 by expiration. The full premium credit of $0.68 would be kept by the premium seller. The risk of $4.32 would be incurred if the stock dropped below the $92.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 79.02 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Party drug Ketamine could help treat severe depression- research
Wed, 02 Apr 2014 23:01:00 GMT
Is Dividend Machine Johnson & Johnson A Buy?
Wed, 02 Apr 2014 22:58:29 GMT
Entia: An Iron-Clad Opportunity in a Billion Dollar Market
Wed, 02 Apr 2014 15:16:00 GMT
Accesswire – WHITEFISH, MT / April 2, 2014 / Iron is an essential trace metal used throughout the human body. For example, iron is an essential component in a protein called hemoglobin that’s responsible for carrying …
Johnson & Johnson Should See Continued Top-Line Growth
Wed, 02 Apr 2014 09:43:42 GMT
FDA defends generic drug label proposal at U.S. House hearing
Tue, 01 Apr 2014 22:58:52 GMT
Reuters – The U.S. Food and Drug Administration on Tuesday defended its proposal to require generic drugmakers to update the prescribing information on their products if they become aware of new safety information, a move the industry says will open them to product liability lawsuits and raise drug costs. Speaking at a hearing before a U.S. House of Representatives health subcommittee, Dr. Janet Woodcock, the FDA's top pharmaceuticals official, said the move is needed to “create parity” between branded and generic drug makers regarding labeling changes. Generic drugmakers are not currently allowed to alter the labels on their products without prior agency approval since generic drugs are supposed to be the same as their brand name counterparts, from the active ingredient to dose strength to the information on the label.
Related Posts
Also on Market Tamer…
Follow Us on Facebook